Niagen Bioscience, Inc. — Director's Dealing 2010

May 25, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2010-05-20

Reporting Person: Varvaro Thomas C (Chief Finanical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	614250	Disposed	2020-05-20	Common Stock (614250)	Direct
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	614250	Disposed	2020-05-20	Common Stock (614250)	Direct
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	200000	Disposed	2020-05-20	Common Stock (200000)	Direct
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	200000	Disposed	2020-05-20	Common Stock (200000)	Direct
2010-05-20	Employee Stock Options (right to buy)1	$1.545	A	75000	Disposed	2010-05-20	Common Stock (75000)	Direct

Footnotes

F1: Options vest 33 1/3% over three years beginning on May 20, 2011

F2: Options vest 33 1/3% over three years beginning on May 20, 2011; provided further that, these options are only exercisable based on the percentage of warrants exercised as of such vesting date that were issued under that certian Subscription Agreement, dated as of April 22, 2010, between the Issuer and the subscribers named therein. Specifically, if 25% to 49.9% of such warrant have been exercised, then 25% of these options are exercisable; if 50% to 74.9% of such warrant have been exercised, then 50% of these options are exercisable; and if 75% or more of such warrants have been exercised, then 100% of these options are exercisable

F3: Options vest over four years with cliff vesting of 25% on May 20, 2011 and 1/36 of the total vesting per month over the remaining three years